This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Juno Therapeutics Inc.
Drug Names(s): CD22-targeted CAR T cell, JCAR-018
Description: Opus and Juno are developing a CD22-targeted CAR T cell product.
The CD22-targeted CAR T cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio.
Juno and Opus
In December 2014, Juno Therapeutics announced that it entered into an agreement to obtain a license from Opus Bio for a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. The CD22-targeted CAR T cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio.
Juno and Celgene
In June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of immunotherapies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno's oncology and cell therapy auto-immune product candidates, including Juno's CD19 and CD22 directed CAR-T...See full deal structure in Biomedtracker
Partners: Opus Bio Celgene Corporation
Additional information available to subscribers only: